MedTrace Logo

Tapering of Inhaled Corticosteroids in Tezepelumab-treated Asthma patieNts: Impact on Clinical Outcomes

NCT07713498 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 61

Last updated 2026-07-21

No results posted yet for this study

Summary

To evaluate the relationship between starting tezepelumab treatment followed by tapering of inhaled corticosteroid (ICS) and ICS dose, metabolic outcomes, asthma control and exacerbation rate in a real world setting

Conditions

Interventions

OTHER

Tapering of inhaled corticosteroid (ICS) treatment

All patients that have started tezepelumab treatment are eligible for tapering of ICS, since it is part of standard care.

Sponsors & Collaborators

  • Franciscus Gasthuis

    lead OTHER

Principal Investigators

  • Gert-Jan Braunstahl, Dr. · Franciscus Gasthuis & Vlietland

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-01
Primary Completion
2027-10-31
Completion
2027-10-31
FDA Drug
Yes

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07713498 on ClinicalTrials.gov